CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed

Simply Wall St.12-20

CG Oncology recently reported topline data from its BOND-003 and CORE-004 trials of investigational therapy cretostimogene in non-muscle invasive bladder cancer, showing encouraging efficacy measures,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592139541?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-20 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592139541","market":"sg","top_or_hot":-1,"title":"CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>CG Oncology recently reported topline data from its BOND-003 and CORE-004 trials of investigational therapy cretostimogene in non-muscle invasive bladder cancer, showing encouraging efficacy measures,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-20 05:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CG Oncology recently reported topline data from its BOND-003 and CORE-004 trials of investigational therapy cretostimogene in non-muscle invasive bladder cancer, showing encouraging efficacy measures,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGON","symbol_name":"CG Oncology Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib","article_id":"2592139541","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-is-down-87-after-strong-cretostimogene-nmib","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592139541","pubTimestamp":1766179072,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CG Oncology recently reported topline data from its BOND-003 and CORE-004 trials of investigational therapy cretostimogene in non-muscle invasive bladder cancer, showing encouraging efficacy measures, a consistent safety profile, and largely localized, low-grade bladder-related adverse events in patients across multiple high-risk settings.\nThe data, which will be featured as late-breaking abstracts at the Society of Urologic Oncology meeting, highlight high complete response rates in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGON":"CG Oncology Inc.","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CG":"凯雷","BK4135":"资产管理与托管银行","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","AI":"C3.ai, Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Cretostimogene NMIBC数据强劲后，CG Oncology(CGON)股价下跌8.7%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGON":1.5,"AI":0.6,"CG":1.5},"content_text":"CG Oncology recently reported topline data from its BOND-003 and CORE-004 trials of investigational therapy cretostimogene in non-muscle invasive bladder cancer, showing encouraging efficacy measures, a consistent safety profile, and largely localized, low-grade bladder-related adverse events in patients across multiple high-risk settings. The data, which will be featured as late-breaking abstracts at the Society of Urologic Oncology meeting, highlight high complete response rates in BCG-naive patients and reinforce CG Oncology’s broader Phase 3 program in non-muscle invasive bladder cancer. We’ll now examine how these promising cretostimogene efficacy and safety results shape CG Oncology’s investment narrative over the past week. AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.What Is CG Oncology's Investment Narrative?For CG Oncology, the core investment belief is that cretostimogene can become a meaningful option in non-muscle invasive bladder cancer and eventually justify a business that is still almost entirely pre-revenue, loss making and valued primarily on future trial outcomes. The new BOND-003 and CORE-004 data slot directly into that story by strengthening the near-term catalyst stack around Phase 3 readouts and potential regulatory interactions, even if the immediate share price pullback suggests the market is still debating durability and competitive positioning. With revenue at about US$2.2 million against a nine‑month net loss above US$119 million, the biggest near-term risks remain clinical, regulatory and financing related, especially if any part of the broader Phase 3 program fails to reproduce these efficacy and safety signals at scale. However, one key funding risk from the company’s ongoing losses is easy to miss at first glance.\n\nDespite retreating, CG Oncology's shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesCGON 1-Year Stock Price Chart The single Simply Wall St Community fair value estimate sits very far above CG Oncology’s current US$38 share price, underscoring how widely opinions can differ. Set that against the company’s small revenue base, sizeable losses and trial dependent catalysts, and it becomes clear why you may want to weigh several viewpoints before forming your own view on CGON’s prospects.Explore another fair value estimate on CG Oncology - why the stock might be worth over 10x more than the current price!Build Your Own CG Oncology NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your CG Oncology research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free CG Oncology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CG Oncology's overall financial health at a glance.Want Some Alternatives?Our daily scans reveal stocks with breakout potential. Don't miss this chance:These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592139541","isCrawlerRequest":true}